With its advanced algorithm that provides autocorrections every 5 minutes, the latest data demonstrated that the MiniMed™ 780G system decreased rates of early morning hyperglycemia, known as dawn ...
The first study by Dr. Goran Petrovski, MD, PhD, of Sidra Medicine, randomly assigned adolescents using the MiniMed™ 780G system (n=34) into two groups, with some entering a fixed pre-set number of ...
Mealtimes are one of the biggest challenges for people living with type 1 diabetes and frequently linked to diabetes distress.1,2 The constant need for decision-making and mental load around ...
Data from the LENNY trial, recently published in The Lancet Diabetes & Endocrinology, demonstrated the safety and efficacy i of the MiniMed™ 780G system in children aged 2-6 years old with type 1 ...
Available in Europe since 2020, this new system delivers the strongest clinical outcomes and best user experience to-date within the Medtronic family of pumps "Mealtimes prove to be one of the biggest ...
The MarketWatch News Department was not involved in the creation of this content. NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack ...
Medtronic plc MDT announced one-year data from the ADAPT study -- the first multi-national randomized controlled study evaluating the performance of the MiniMed 780G advanced hybrid closed loop ...
Credit: Getty Images. The first shipments of the MiniMed 780G system are expected this summer with preorders beginning on May 15, 2023. The Food and Drug Administration (FDA) has approved the ...
NORTHRIDGE, Calif., March 10, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a global leader in full stack insulin delivery, today announced CE (Conformité Européenne) Mark for use of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results